Dogwood Therapeutics Inc宣布通过与Serpin Pharma的全股票交易,成功获得SP16项目的免版税许可权。此次交易将为Dogwood Therapeutics Inc在相关治疗领域的发展提供重要支持。
Dogwood Therapeutics Inc宣布通过与Serpin Pharma的全股票交易,成功获得SP16项目的免版税许可权。此次交易将为Dogwood Therapeutics Inc在相关治疗领域的发展提供重要支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.